Navigation Links
Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine's Cotara(R) for Treatment of Brain Cancer
Date:9/2/2009

BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being presented today at the XIV World Congress of Neurological Surgery Annual Meeting by Dr. Deepak Gupta, assistant professor of neurosurgery at the All India Institute of Medical Sciences (AIIMS) in New Delhi on behalf of the Cotara study team that includes Drs. A.K. Mahapatra, Ashish Suri and C.S. Bal.

Dr. Gupta will present interim data for 10 recurrent GBM patients at first relapse treated at AIIMS as part of an ongoing 40 patient Phase II clinical trial. Eight males and two females with a mean age of 51 years received a single intratumoral infusion of Cotara. Currently, follow-up duration ranges from between seven to over 73 weeks with an interim median recurrence-free survival of 33 weeks and an interim median overall survival of 41 weeks. Expected survival for patients with GBM is approximately 24 weeks from time of disease recurrence. Based on this interim data, the study authors conclude that Cotara appears to be feasible, tolerable and has encouraging signs of efficacy in recurrent GBM patients.

"This interim data from our Phase II trial suggests that Cotara has the potential to be a valuable new therapy for patients with glioblastoma, a devastating disease with few treatment options," said Dr. A.K. Mahapatra, pr
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
2. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
3. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
4. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
5. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
6. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
7. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
10. Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
(Date:8/28/2014)... 29, 2014 AltMed , ... industry precision to the development and production of ... its primary location in Sarasota County. , ... a total commitment to attracting new industry and ... says David Wright, President and CEO of AltMed. ...
(Date:8/28/2014)... When David Gergen, President of Pro Player ... was asked to publicly support Mr. Brnovich in his ... seat in the State of Arizona, Mr. Gergen could ... Hall of Fame wide receiver Roy Green in addition ... Green, Kennard and Walczak are members of Pro Player ...
(Date:8/28/2014)... New Energy Works Timberframe plans for a ... country to Log & Timber Home Shows starting in ... Energy Works team will invite the shows’ attendees into ... expertise, project images, and their new 2015 project calendar. ... Mid-West Representative, will present “A fun-fill odyssey: Realizing your ...
(Date:8/28/2014)... 42-year-old investment banker arrives at the emergency department ... He drinks alcohol every dayoften at business lunches, ... health, he decided to quit drinking and had ... emergency. , It,s a common scenario in emergency ... alcohol consumption and develops withdrawal. , Withdrawal is ...
(Date:8/28/2014)... 28, 2014 On August 21, the ... its 2013 Annual Report, featuring the organization’s audited financial ... , According to the report, in 2013, the ... programs versus 14 cents on fundraising and administration. ... a minimum,” wrote the Foundation’s chief executive officer, Melinda ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... 2008) -- Pancreatic cancer is one of the ... in a major step forward, researchers at NewYork-Presbyterian ... radiation therapy prior to surgery nearly doubles survival ... "Patients who received pre-surgical (neoadjuvant) radiation had almost ...
... unmatched in its ability to deliver a ... across clinical settings to aid decision-making and ... announced that it earned two of Healthcare ... four of the five categories, ICA was ...
... Consumption and Kidney Cancer , There is no ... kidney cancer, according to a pooled analysis of prospective ... increasing worldwide, but the cause of the increase remains ... to an association between consumption of fat, protein, and ...
... , HARRISBURG, Pa., Nov. 25 In ... School District, the Pennsylvania Department of Health held vaccination clinics ... School on Nov. 19 and Nov. 24. , ... given to approximately 560 parents, students, and staff after an ...
... those with poor glucose control likely to have artery disease ... earlier research, a new study has identified a genetic ... in type 2 diabetes patients with poor sugar glucose (glycemic) ... on a genetic chromosome known as chromosome 9p21 are ...
... to blame, study concludes , , TUESDAY, Nov. 25 (HealthDay News) ... cancer for older women, according to a new study that ... their mammogram habits. , The weight itself is to blame ... who are above their healthy weight have higher levels of ...
Cached Medicine News:Health News:Radiation before surgery improves pancreatic cancer outcomes 2Health News:Radiation before surgery improves pancreatic cancer outcomes 3Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 2Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 3Health News:Also in the Nov. 25 JNCI 2Health News:Also in the Nov. 25 JNCI 3Health News:Also in the Nov. 25 JNCI 4Health News:Chromosome Linked to Diabetics' Heart Risks 2Health News:Weight Boosts Older Women's Breast Cancer Risk 2Health News:Weight Boosts Older Women's Breast Cancer Risk 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: